Carrie-Lynn Langlais Furr, PhD, RAC is cofounder of Bacteriophage & Drug Development Consultants. She is also a Scientific Advisor for CARB-X and an Editor of PHAGE Therapy, Applications, and Research journal. Previously, she was Vice President of Regulatory Affairs & Program Management for a biotech developing phage therapies and collaboratively worked with over 30 pharmaceutical companies at various stages of development and for a broad range of indications while in the CRO industry for a decade.

Dr. Furr's major accomplishments include obtaining 7 FDA market approvals (1 biologic-device and 6 drugs), 8 INDs, including phage therapy, which enabled clinical trials to commence, Orphan Designation for a gene therapy, 2 international phage therapy Expanded Access programs, and several formal health authority interactions and negotiations (including for phage therapies).

Dr. Furr’s publications cover peer-reviewed phage characterization and phage therapy clinical case studies. She holds a PhD in Biochemistry & Biophysics from Texas A&M University and studied under Professor Ryland Young to elucidate the antibiotic mechanism of the ssRNA bacteriophage Qbeta. Dr. Furr has held Regulatory Affairs Certification from the Regulatory Affairs Professionals Society since 2009.